Thrombospondin-1 and cutaneous melanoma

被引:16
|
作者
Trotter, MJ
Colwell, R
Tron, VA
机构
[1] Univ Calgary, Calgary Lab Serv, Dept Pathol & Lab Med, Calgary, AB T3C 0J5, Canada
[2] Univ Alberta, Dept Pathol & Lab Med, Edmonton, AB T6G 2M7, Canada
关键词
D O I
10.1007/s10227-002-0164-8
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background: Thrombospondins (TSPs) are recognized as important glycoproteins that regulate a wide variety of cell functions and interactions. TSPs in malignant tumors can both enhance and inhibit tumor progression, invasion, and metastasis, depending on cell type, stromal interactions, and microenvironment. These proteins are potential targets for anticancer therapy. Objective: The aim of our article is to review the role of thrombospondin-1 (TSP1) in cutaneous melanoma. Conclusions: TSP1 expression is variable in melanoma cell lines and tumors. Similar to findings in other human cancers, expression of TSP1 by melanoma cells usually inhibits tumor progression via the antiangiogenic effect of TSP1 Conversely, stromal TSP1 overexpression in melanoma is a poor prognostic factor associated with decreased survival. Understanding the interactions of TSP1 with other melanoma- and matrix-associated proteins should provide new prognostic indices and possible therapeutic targets for melanoma treatment.
引用
收藏
页码:136 / 141
页数:6
相关论文
共 50 条
  • [31] Suppression of Thrombospondin-1 Expression During Uveal Melanoma Progression and Its Utilization as Potential Therapeutic
    Wang, S.
    Albert, D. M.
    Nekhra, A.
    Sorenson, C. M.
    Sheibani, N.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2010, 51 (13)
  • [32] Role of thrombospondin-1 and thrombospondin-2 in cardiovascular diseases (Review)
    Zhang, Kaijie
    Li, Miaomiao
    Yin, Li
    Fu, Guosheng
    Liu, Zhenjie
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2020, 45 (05) : 1275 - 1293
  • [33] THROMBOSPONDIN-1 AND THROMBOSPONDIN-2 ARE EXPRESSED AS BOTH HOMO AND HETEROTRIMERS
    OROURKE, KM
    LAHERTY, CD
    DIXIT, VM
    MOLECULAR BIOLOGY OF THE CELL, 1992, 3 : A224 - A224
  • [34] A phase II study of ABT-510 (thrombospondin-1 analog) for the treatment of metastatic melanoma
    Markovic, Svetomir N.
    Suman, Vera J.
    Rao, Ravi A.
    Ingle, James N.
    Kaur, Judith S.
    Erickson, Lori A.
    Pitot, Henry C.
    Croghan, Gary A.
    McWilliams, Robert R.
    Merchan, Jaime
    Kottschade, Lisa A.
    Nevala, Wendy K.
    Uhl, Cindy B.
    Allred, Jacob
    Creagan, Edward T.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2007, 30 (03): : 303 - 309
  • [35] Thrombospondin-1, PECAM-1, and regulation of angiogenesis
    Sheibani, N
    FASEB JOURNAL, 2006, 20 (04): : A21 - A22
  • [36] Thrombospondin-1, PECAM-1, and regulation of angiogenesis
    Sheibani, N
    Frazier, WA
    HISTOLOGY AND HISTOPATHOLOGY, 1999, 14 (01) : 285 - 294
  • [37] Mechanism of inhibition of tumoral angiogenesis by thrombospondin-1
    Cuenca, BJ
    NEFROLOGIA, 2003, 23 : 49 - 53
  • [38] The role of thrombospondin-1 in tumor progression and angiogenesis
    Tuszynski, GP
    Nicosia, RF
    BIOESSAYS, 1996, 18 (01) : 71 - 76
  • [39] Expression of thrombospondin-1 and VEGF in gastric carcinoma
    Lee, Wan-Sik
    Park, Chang-Hwan
    Joo, Young-Eun
    Kim, Hyun-Soo
    Choi, Sung-Kyu
    Rew, Jong-Sun
    Kim, Sei-Jong
    Park, Chang-Soo
    GASTROENTEROLOGY, 2006, 130 (04) : A418 - A419
  • [40] Thrombospondin-1 expression in renal allograft rejection
    Roberts, ISD
    Farrington, C
    Dziobon, M
    Brenchley, PEC
    Short, CD
    Canfield, AE
    JOURNAL OF PATHOLOGY, 1997, 181 : A53 - A53